Dr. Reddy's Laboratories Limited (RDY)

NYSE: RDY · IEX Real-Time Price · USD
76.83
-0.26 (-0.34%)
Feb 27, 2024, 4:00 PM EST - Market closed
-0.34%
Market Cap 12.95B
Revenue (ttm) 2.99B
Net Income (ttm) 548.26M
Shares Out 166.52M
EPS (ttm) 3.27
PE Ratio 20.41
Forward PE 20.92
Dividend $0.97 (1.26%)
Ex-Dividend Date Jul 28, 2023
Volume 141,674
Open 77.08
Previous Close 77.09
Day's Range 76.82 - 77.50
52-Week Range 52.24 - 77.72
Beta 0.35
Analysts Buy
Price Target 80.00 (+4.13%)
Earnings Date Jan 30, 2024

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The ... [Read more]

Sector Healthcare
Founded 1984
Employees 25,863
Stock Exchange NYSE
Ticker Symbol RDY
Full Company Profile

Financial Performance

In 2022, RDY's revenue was 245.88 billion, an increase of 14.69% compared to the previous year's 214.39 billion. Earnings were 45.07 billion, an increase of 91.22%.

Financial numbers in INR Financial Statements

Analyst Forecast

According to one analyst, the rating for RDY stock is "Buy" and the 12-month stock price forecast is $80.0.

Price Target
$80.0
(4.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Dr. Reddy's Q3 & 9M FY24 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY24--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.

27 days ago - Business Wire

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #AmyrisInc--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands.

7 weeks ago - Business Wire

Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DJSIWorld--Dr. Reddy's has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agen...

2 months ago - Business Wire

Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

HOUSTON & HYDERABAD, India & BASEL, Switzerland--(BUSINESS WIRE)--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: ...

Other symbols: COYA
2 months ago - Business Wire

India's Dr. Reddy's R&D centre being inspected by US FDA

India's Dr Reddy's on Tuesday said that its research and development centre in Hyderabad is being inspected by the U.S. Food and Drug Administration.

3 months ago - Reuters

Dr. Reddy's Q2 FY24 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023.

4 months ago - Business Wire

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

7 months ago - Business Wire

Dr. Reddy's Q1 FY24 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2023.

7 months ago - Business Wire

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #BiologicsLicenseApplication--Dr. Reddy's proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA.

8 months ago - Business Wire

Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRL_TC--Dr. Reddy's announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

9 months ago - Business Wire

Dr. Reddy's Q4 & FY23 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023.

10 months ago - Business Wire

Dr. Reddy's: A Profitable, Predictable Margin Expander

The Profitable Predictable Margin Expanders screener on GuruFocus has been a helpful one for me when searching for quality stocks that show solid growth. It does what the name suggests - it sorts thro...

10 months ago - GuruFocus

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced the launch of Regadenoson Injection in the U.S. market.

10 months ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces the launch of Treprostinil Injection in the U.S.

11 months ago - Business Wire

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg fu...

Other symbols: COYA
1 year ago - Business Wire

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio

HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma's U.S. generic prescription product por...

1 year ago - Business Wire

Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Bloomberg--Dr. Reddy's Laboratories Ltd announced major back-to-back recognitions in gender equality and sustainability.

1 year ago - Business Wire

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. R...

1 year ago - Business Wire

Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...

1 year ago - Business Wire

Dr. Reddy's Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...

1 year ago - Business Wire

World Economic Forum Recognises Dr. Reddy's Hyderabad Factory as Part of its Global Lighthouse Network

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #4IR--World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network.

1 year ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Affordablemedicines--Dr. Reddy's Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.

1 year ago - Business Wire

Plaintiff in first Zantac lawsuit set for trial drops case

The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Other symbols: BAYRYGSK
1 year ago - Reuters

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Alcon--Dr. Reddy's Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayb...

1 year ago - Business Wire

Demand for affordable health services is rising, says pharmaceutical company

Erez Israeli of Dr. Reddy's Laboratories says affordable medicine is very important in times of economic volatility and discusses the decline in its growth margins.

1 year ago - CNBC International TV